EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022
EpiCast Report: Acute Coronary Syndrome (ACS...
3.4 Global Trends - Ua 33
3.5 Forecast Methodology 35
3.5.1 Forecast Case Flow Map 37
3.5.2 Sources Used 43
3.5.3 Sources ...
Upcoming SlideShare
Loading in …5
×

Epi cast report acute coronary syndrome (acs) - epidemiology forecast to 2022

217 views
119 views

Published on

http://www.researchmoz.us/epicast-report-acute-coronary-syndrome-acs-epidemiology-forecast-to-2022-report.html

Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
217
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Epi cast report acute coronary syndrome (acs) - epidemiology forecast to 2022

  1. 1. EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022 EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022 Summary Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a persons symptoms, changes in the ST-tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). These three disease entities differ in their clinical characteristics, treatment approaches, and survival probabilities. The epidemiology of ACS in the 7MM has changed significantly during the past two decades and varies between the western and Japanese markets. In order to capture the country-specific trends and provide detailed patient population segmentation, GlobalData epidemiologists built separate forecasts for (myocardial infarction) (MI) and UA in the 7MM and used a case-flow methodology to determine the number of cases that survived until hospital discharge and for one year after hospital discharge. GlobalData epidemiologists forecast that in the 7MM, the hospitalized incident cases of ACS will increase from 1.29 million cases in 2012 to 1.43 million cases in 2022 at the rate of 1.04% per year. The US constitutes around 40% of the total hospitalized incident ACS cases in the 7MM and will be the market with the highest number of cases during the forecast period. The majority of the cases occurred in men (58.15%) and in those ages =65 years (69.01%). For the 7MM, about 33% of the ACS cases were STEMI, 44% were NSTEMI, and 23% were UA. The proportions varied depending on the market. Scope The ACS EpiCast Report provides an overview of the ACS risk factors and comorbidities, a discussion of the ACS global and historical trends, and a 10-year epidemiological patient forecast for ACS from 2012 to 2022 in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). The epidemiological patient forecast includes - Hospitalized incident cases of ACS, segmented by STEMI, NSTEMI, and UA - ACS cases that survived until hospital discharge, segmented by STEMI, NSTEMI, and UA - ACS cases that survived for one year post-hospital discharge, segmented by STEMI, NSTEMI, and UA - Diagnosed prevalent cases of myocardial infarction (MI) segmented by STEMI and NSTEMI from 2012 to 2022 in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK) - The ACS epidemiology report is written and developed by Masters- and PhD-level epidemiologists. - The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM. Reasons to buy - Develop business strategies by understanding the trends shaping and driving the global ACS market. - Quantify patient populations in the global ACS market to improve product design, pricing, and launch plans. - Organize sales and marketing efforts by identifying the patient segmentations that present the best opportunities for ACS therapeutics in each of the markets covered. - Identify the number of ACS cases survived to key time periods. 1 Table Of Contents 1 Table Of Contents 4 1.1 List Of Tables 7 1.2 List Of Figures 8 2 Introduction 10 2.1 Catalyst 10 2.2 Upcoming Reports 10 3 Epidemiology 11 3.1 Disease Background 11 3.2 Risk Factors And Comorbidities 12 3.2.1 Controlling Hypertension Can Decrease The Chd Incidence By 20-25% 13 3.2.2 Every 1% Decrease In Cholesterol Levels Is Associated With A 2% Decrease In The Chd Risk 14 3.2.3 Women Who Have Diabetes Have A Higher Risk Of Developing Chd Than Men With Diabetes 15 3.2.4 Cigarette Smoking Increases The Risk Of Chd And Also Increases The Risk Of Developing Other Risk Factors For Chd 16 3.2.5 Obese And Physically Inactive Persons Are More Likely To Develop Chd Through An Increased Risk Of Developing The Traditional Risk Factors 16 3.2.6 Non-modifiable Risk Factors, Such As Family History, Age, And Sex, Contribute To Chd Development 17 3.2.7 Comorbidities 17 3.3 Global Trends - Mi 18 3.3.1 Mi Incidence And Mortality Trends 18 3.3.2 Stemi And Nstemi Trends 29 3.3.3 Trends In Mi Mortality And Case-fatality Rates 30 3.3.4 Mi Prevalence 32 EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022
  2. 2. 3.4 Global Trends - Ua 33 3.5 Forecast Methodology 35 3.5.1 Forecast Case Flow Map 37 3.5.2 Sources Used 43 3.5.3 Sources Not Used 52 3.5.4 Forecast Assumptions And Methods, Hospitalized Mi Incident Cases 53 3.5.5 Forecast Assumptions And Methods, Stemi And Nstemi Cases That Survived Until Hospital Discharge 59 3.5.6 Forecast Assumptions And Methods, Stemi And Nstemi Cases That Survived For One Year After Discharge 60 3.5.7 Forecast Assumptions And Methods, Diagnosed Prevalent Cases Of Mi 62 3.5.8 Forecast Assumptions And Methods, Hospitalized Cases Of Ua 64 3.5.9 Forecast Assumptions And Methods, Ua Cases That Survived Until Hospital Discharge And For One Year Post-discharge 65 3.6 Epidemiological Forecast For Acs (2012-2022) - Hospitalized Incident Cases 66 3.6.1 Hospitalized Incident Cases Of Acs 66 3.6.2 Age-specific Hospitalized Incident Cases Of Acs 68 3.6.3 Sex-specific Hospitalized Incident Cases Of Acs 70 3.6.4 Hospitalized Incident Cases Of Acs By Stemi, Nstemi, And Ua 72 3.6.5 Acs Cases That Survived Until Hospital Discharge And For One Year 75 3.6.6 Age-specific Acs Cases That Survived Until Hospital Discharge 78 3.6.7 Age-standardized Incidence Of Acs 79 3.7 Epidemiological Forecast For Mi (2012-2022) - Prevalent Cases 81 3.7.1 Diagnosed Prevalent Cases Of Mi 81 3.7.2 Diagnosed Prevalent Cases Of Mi Segmented By Stemi And Nstemi 83 3.7.3 Age-specific Diagnosed Prevalent Cases Of Mi 84 3.7.4 Sex-specific Diagnosed Prevalent Cases Of Mi 86 3.7.5 Age-standardized Diagnosed Prevalence Of Mi 87 3.8 Discussion 89 3.8.1 Epidemiological Forecast Insight 89 3.8.2 Limitations Of The Analysis 90 3.8.3 Strengths Of The Analysis 91 4 Appendix 93 4.1 Bibliography 93 4.2 About The Authors 104 4.2.1 Epidemiologists 104 4.2.2 Reviewers 104 4.2.3 Global Director Of Epidemiology And Health Policy 105 4.2.4 Global Head Of Healthcare 106 4.3 About Globaldata 107 4.4 About Epicast 107 4.5 Disclaimer 107 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022

×